Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.56 |
| ▸ | ERO1A | Q96HE7 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496455 | 0.90 | ALDH1A1 (0.58) | NPC1RAB9ANPSR1KDM4EMAPT | |
| SCHEMBL3496942 | 0.89 | NPC1 (0.55) | NPC1RAB9ANPSR1KDM4EMAPT | |
| SCHEMBL3497253 | 0.88 | RAB9A (0.55) | NPC1RAB9ANPSR1KDM4EMAPT | |
| SCHEMBL14875905 | 0.86 | ALDH1A1 (0.76) | RAB9ANPSR1KDM4EMAPTPOLB | |
| SCHEMBL10051825 | 0.85 | JAK2 (0.57) | NPC1RAB9ANPSR1KDM4EMAPT | |
| SCHEMBL3497917 | 0.83 | KDM4E (0.49) | NPC1RAB9ANPSR1KDM4EMAPT | |
| SCHEMBL7899684 | 0.82 | KDM4E (1.00) | NPC1RAB9ANPSR1KDM4EMAPT | |
| SCHEMBL25782243 | 0.82 | ALOX15 (0.56) | NPC1RAB9ANPSR1KDM4EMAPT | |
| SCHEMBL2824619 | 0.82 | NPSR1 (0.45) | NPC1RAB9ANPSR1KDM4EMAPT | |
| SCHEMBL1681700 | 0.82 | JAK2 (0.56) | NPC1RAB9ANPSR1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023101556-A1 | NOVEL INHIBITORS OF ASPARTATE TRANSCARBAMOYLASE (ATCASE) AND COMPOSITIONS, METHODS AND USES RELATED THERETO. | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-06-08 | — | — | WO | disclosed |
| CN-103958521-B | Pyrimidin-4-one derivatives and their use in the treatment, alleviation or prevention of viral diseases | 弗·哈夫曼-拉罗切有限公司 | 2016-10-19 | — | — | CN | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2009011-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TNNC1, CPT1B, TNNI3 | NPC1 713/4885RAB9A 3530/4885NPSR1 2969/4885 |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | NPC1 590/4885RAB9A 1626/4885NPSR1 4109/4885 |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | NPC1 1194/4885RAB9A 3246/4885NPSR1 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.